Related Experiment Video
Updated: Jul 15, 2026

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
Published on: September 17, 2015
Myocyte nitric oxide synthase 2 contributes to blunted beta-adrenergic response in failing human hearts by decreasing
Mark T Ziolo1, Lars S Maier, Valentino Piacentino
1Department of Physiology, Loyola University Medical Center, Maywood, Ill 60153, USA.
Background:
Human heart failure (HF) usually exhibits blunted response to beta-adrenergic receptor (AR) stimulation. Here, we examined whether expression of nitric oxide synthase-2 (NOS2, or inducible NOS) contributes to this loss of inotropic reserve in human HF.
Methods And Results:
Failing human hearts were obtained at transplantation. Contraction and [Ca2+]i measurements were performed in isolated cardiac myocytes and trabeculae. In HF myocytes and muscle, isoproterenol (ISO), a beta-AR agonist, led to small inotropic and lusitropic responses. Specific inhibition of NOS2 by aminoguanidine (AG) or L-NIL dramatically increased the ISO-induced inotropy and lusitropy, such that the ISO+AG response in HF approached that seen with ISO alone in nonfailing human myocytes or muscles. Ca2+ transient data directly paralleled these results, indicating that altered cellular Ca2+ handling is responsible. In nonfailing human hearts, NOS2 inhibition had no effects. In addition, NOS2 inhibition also had no effect in 30% of failing hearts, but in these myocytes and muscles, the ISO response alone was similar to that of nonfailing hearts. In line with these functional findings, NOS2 protein expression measured by Western blotting was induced in HF when AG/L-NIL had a functional effect but not when AG/L-NIL had no effect on contractility and Ca2+ transients.
Conclusions:
NOS2 expression strongly limited ISO-induced increases in contraction, twitch Delta[Ca2+]i, and lusitropy in trabeculae and isolated myocytes from failing human hearts. Thus, the beta-AR hyporesponsiveness in human HF is mediated in large part by NO (or related congeners) produced within cardiac myocytes via NOS2.
Insights
Nitric oxide synthase-2 (NOS2) in human heart failure limits response to beta-adrenergic stimulation. Inhibiting NOS2 restores this response, suggesting NOS2 mediates beta-AR hyporesponsiveness in heart failure.
Area of Science:
- Cardiology
- Molecular Biology
- Physiology
Background:
- Human heart failure (HF) is characterized by a diminished response to beta-adrenergic receptor (AR) stimulation.
- The role of nitric oxide synthase-2 (NOS2) in this blunted response remains unclear.
Purpose of the Study:
- To investigate whether NOS2 expression contributes to the loss of inotropic reserve in human HF.
- To determine if NOS2 inhibition can restore beta-AR responsiveness in failing human hearts.
Main Methods:
- Human failing and nonfailing hearts were obtained at transplantation.
- Cardiac myocyte and trabeculae contractility and intracellular calcium ([Ca2+]i) transients were measured.
- The effects of beta-AR agonist isoproterenol (ISO) and NOS2 inhibitors (aminoguanidine or L-NIL) were assessed.
Main Results:
- In failing hearts, ISO produced minimal inotropic and lusitropic effects.
- NOS2 inhibition significantly enhanced ISO-induced contractility and [Ca2+]i transients, approaching levels seen in nonfailing hearts.
- NOS2 protein expression was elevated in failing hearts where inhibition had a functional effect.
Conclusions:
- NOS2 expression significantly limits beta-AR-mediated increases in contractility and calcium handling in human HF.
- The beta-AR hyporesponsiveness in human HF is largely mediated by nitric oxide produced via NOS2 within cardiac myocytes.
Related Concept Videos
Nitric Oxide Signaling Pathway
Antihypertensive Drugs: Action of Calcium Channel Blockers
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: β-Blockers
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Heart Failure II: Pathophysiology

